Traws Pharma (TRAW) Price & Analysis

Compare

1,858 Followers

TRAW Stock Chart & Stats

$2.20

-$0.87(-9.63%)

At close: Jan 08 4:00 PM EST

$2.20

-$0.87(-9.63%)

Day’s Range― - ―

52-Week Range$0.97 - $19.44

Previous CloseN/A

Volume35.69K

Average Volume (3M)206.36K

Market Cap

$10.19M

Enterprise Value-$4.47M

Total Cash (Recent Filing)$13.08M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)<0.1

Beta0.68

Next Earnings

Mar 12, 2026

EPS Estimate

-1.91

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding7,990,867

10 Day Avg. Volume403,079

30 Day Avg. Volume206,356

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-0.44

Price to Sales (P/S)61.01

P/FCF Ratio-0.46

Enterprise Value/Market Cap-0.44

Enterprise Value/Revenue-1.60

Enterprise Value/Gross Profit-1.60

Enterprise Value/Ebitda0.41

Forecast

1Y Price Target

$8.00

Price Target Upside263.64% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsTraws Pharma reported positive interim data from a Phase 2 study evaluating ratutrelvir, showing no COVID-19 symptom or virologic rebound events and fewer adverse events compared to PAXLOVID.

Market PotentialRatutrelvir is designed to address the need for effective oral COVID-19 treatments in a market exceeding $6 billion, constrained by existing agents' limitations.

Strategic FocusTraws Pharma's strategic shift towards antiviral development is supported by a strong pipeline led by ratutrelvir and tivoxavir marboxil, with completed Phase 1 studies and planned Phase 2 development.

Bears Say

Traws Pharma News

Traws Pharma reports ‘positive’ interim data with ratutrelvir vs. paxlovid

Traws Pharma (TRAW) announced that interim data with ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, demonstrated a...

4d ago

TRAW

Traws Pharma initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Brandon Folkes initiated coverage of Traws Pharma (TRAW) with a Buy rating and $8 price...

18d ago

TRAW

Promising Phase 2 Results for Ratutrelvir Highlight Clinical and Market Differentiation in COVID-19 Treatment

In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Traws Pharma, with...

4d ago

TRAW

Traws Pharma Reports Positive Phase 2 Trial Results

An announcement from Traws Pharma ( ($TRAW) ) is now available. Traws Pharma announced positive interim results from...

4d ago

TRAW

Traws Pharma Approves Executive Stock Options

The latest announcement is out from Traws Pharma ( ($TRAW) ). On December 12, 2025, Traws Pharma‘s Compensation...

5d ago

TRAW

Traws Pharma Holds Virtual Annual Meeting 2025

Traws Pharma ( ($TRAW) ) has shared an announcement. On November 21, 2025, Traws Pharma held its Annual...

23d ago

TRAW

Traws Pharma Reports Q3 2025 Progress and Cost Reductions

Traws Pharma, Inc. ( ($TRAW) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

TRAW

Traws Pharma Reports Q3 2025 Financial Results

The latest update is out from Traws Pharma ( ($TRAW) ). On November 13, 2025, Traws Pharma announced...

1M ago

TRAW

Traws Pharma reports Q3 EPS (34c) vs ($1.49) last year

Cash and cash equivalents: As of September 30, 2025, the Company had cash and cash equivalents of approximately...

1M ago

TRAW

Traws Pharma’s New COVID-19 Drug Trial: A Potential Game-Changer?

Traws Pharma, Inc. (($TRAW)) announced an update on their ongoing clinical study. Study Overview: Traws Pharma, Inc. is...

2M ago

TRAW

Traws Pharma’s TRX-100 Study: A Potential Game-Changer in Pharmacokinetics

Traws Pharma, Inc. (($TRAW)) announced an update on their ongoing clinical study. Study Overview: Traws Pharma, Inc. is...

2M ago

TRAW

Traws Pharma Approves Executive Stock Options Grant

Traws Pharma ( ($TRAW) ) has provided an update. On October 12, 2025, Traws Pharma‘s Compensation Committee approved...

2M ago

TRAW

Traws Pharma Begins Phase 2 COVID-19 Treatment Study

The latest update is out from Traws Pharma ( ($TRAW) ). On October 14, 2025, Traws Pharma announced...

2M ago

TRAW

Traws Pharma doses first patient with ratutrelvir in Phase 2 COVID studies

Traws Pharma (TRAW) announced the dosing of the first subject in a Phase 2 study to evaluate ratutrelvir,...

2M ago

TRAW

TRAW FAQ

What was Traws Pharma’s price range in the past 12 months?

Traws Pharma lowest stock price was $0.97 and its highest was $19.44 in the past 12 months.

What is Traws Pharma’s market cap?

Traws Pharma’s market cap is $10.19M.

When is Traws Pharma’s upcoming earnings report date?

Traws Pharma’s upcoming earnings report date is Mar 12, 2026 which is in 81 days.

How were Traws Pharma’s earnings last quarter?

Traws Pharma released its earnings results on Nov 13, 2025. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.34.

Is Traws Pharma overvalued?

According to Wall Street analysts Traws Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Traws Pharma pay dividends?

Traws Pharma does not currently pay dividends.

What is Traws Pharma’s EPS estimate?

Traws Pharma’s EPS estimate is -1.91.

How many shares outstanding does Traws Pharma have?

Traws Pharma has 7,990,867 shares outstanding.

What happened to Traws Pharma’s price movement after its last earnings report?

Traws Pharma reported an EPS of -$0.34 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -17.29%.

Which hedge fund is a major shareholder of Traws Pharma?

Currently, no hedge funds are holding shares in TRAW

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Traws Pharma

Traws Pharma (TRAW) is a biotechnology company specializing in the development and commercialization of innovative therapeutics. Operating within the pharmaceutical sector, Traws Pharma focuses on addressing unmet medical needs in areas such as oncology, neurology, and infectious diseases. The company is committed to advancing healthcare through cutting-edge research and development, leveraging both proprietary platforms and strategic collaborations to bring new treatments to market.

Traws Pharma (TRAW) Earnings & Revenues

Historic Earnings Reports

TRAW Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

Traws Pharma has made notable advancements in its antiviral programs, particularly with Ratutrelvir for COVID-19. Regulatory engagement and a significant increase in revenue highlight positive progress. However, challenges such as deferred influenza studies and reduced cash reserves present concerns. Overall, highlights slightly outweigh the lowlights, indicating a cautiously optimistic outlook.View all TRAW earnings summaries

TRAW Stock 12 Month Forecast

Average Price Target

$8.00

▲(263.64% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","14":"$14","27":"$27","7.5":"$7.5","20.5":"$20.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.5,14,20.5,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2023","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.48,2.9046153846153846,3.329230769230769,3.753846153846154,4.178461538461538,4.603076923076923,5.027692307692307,5.452307692307691,5.8769230769230765,6.3015384615384615,6.726153846153846,7.15076923076923,7.575384615384614,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.48,2.9046153846153846,3.329230769230769,3.753846153846154,4.178461538461538,4.603076923076923,5.027692307692307,5.452307692307691,5.8769230769230765,6.3015384615384615,6.726153846153846,7.15076923076923,7.575384615384614,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.48,2.9046153846153846,3.329230769230769,3.753846153846154,4.178461538461538,4.603076923076923,5.027692307692307,5.452307692307691,5.8769230769230765,6.3015384615384615,6.726153846153846,7.15076923076923,7.575384615384614,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.48,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.48,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.75,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.26,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.58,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.99,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.88,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.28,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.14,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >